Introduction {#Sec1}
============

Lung cancer is the leading cause of cancer death worldwide. Visceral pleural invasion (VPI), since 1970s, has been adopted as a T descriptor in the TNM classification and known to be an adverse prognostic factor in non-small cell lung cancer (NSCLC)^[@CR1]--[@CR3]^. The 7th edition TNM staging system of lung cancer recommended the classification of pleural invasion as PL0 if the tumor does not invade past the elastic layer, as PL1 if it invades past the elastic layer, PL2 if it invades to the pleural surface and PL3 if it invades to the parietal pleura^[@CR4]^. PL1 and PL2 were defined as VPI and PL0 was defined as without VPI.

However, the International Association for the Study of Lung Cancer (IASLC) team didn't analysis and validate the prognosis of PL status in the 7th TMN classification of lung cancer because of insufficient data to be submitted^[@CR3]^. Most studies investigated the prognostic value of VPI without distinguishing the extent of VPI (PL1 and PL2)^[@CR5]--[@CR10]^. It is still unclear whether PL1 and PL2 are equivalent and whether they should be combined to define VPI, or how tumors with PL1 and PL2 should be classified. Recently, Chan YL and associates reported resected NSCLC patients with PL2 had significant worse survival than those with PL1 and suggested PL2 to be a potential indication for adjuvant chemotherapy^[@CR11]^. Likewise, Hung J. J. *et al*. reported patients with PL2 had significantly worse overall survival and lower probability of freedom from recurrence than those with PL1 after resection of node-negative NSCLC^[@CR12]^. And some other studies also reached positive results^[@CR13]--[@CR15]^. Contrary to the studies mentioned above, there were some other studies that didn't find the survival difference between PL1 and PL2 patients^[@CR16]--[@CR24]^. Thus, the evidence on this topic remains controversial.

Our previously study has demonstrated that VPI is a consistent adverse prognostic factor in stage I NSCLC patients^[@CR25]^. In this study, we focused on the prognostic significance of PL0, PL1 and PL2 and aimed to answer the question whether PL2 has worse prognosis than PL1 in resected NSCLC patients.

Methods {#Sec2}
=======

Eligibility criteria {#Sec3}
--------------------

Two investigators (Ting Wang and Chengya Zhou) independently evaluated the potential articles through reading titles, abstracts and full text to decide eligibility of studies. The studies were considered to be included if:(1) original cohort studies published from inception to May 9, 2016 without language restrictions; (2) studies comparing survival outcomes between resected NSCLC patients with PL0, PL1 or PL2; (3) studies reporting at least one survival outcome such as overall survival (OS), 5-year survival rate or recurrence free survival (RFS); and (4) study participants having been pathologically diagnosed NSCLC after resection. The following studies were excluded if: (1) studies including cancers other than NSCLC; (2) studies containing no available survival data for analysis; (3) participants in studies receiving neoadjuvant therapy; and (4) studies published as review, letter or other non-original types.

Search strategy {#Sec4}
---------------

An electronic search in PubMed, EMBASE, OVID and the Cochrane Library were conducted from inception to May 9, 2016. The following key words in combination as medical subject heading terms and text words were used: "lung cancer" and "visceral pleural invasion". Potentially relevant articles were identified by reading titles and abstracts. The full texts of the relevant articles were read to determine whether they met the inclusion criteria. The references were also searched to identify relevant studies.

Quality assessment {#Sec5}
------------------

For cohort studies, the 9-star Newcastle-Ottawa Quality Assessment Scale was used to assess the risk of bias^[@CR26]^. This scale is an 8-item instrument that allows for assessment of patient population and selection, study comparability, follow-up, and outcome. Interpretation of the scale is performed by awarding points for high-quality elements. Studies with 5 or more stars were defined as high-quality studies and were included.

Statistical analyses {#Sec6}
--------------------

Data was extracted using a unified form and study information including author name, study year, study area, sample size, tumor size, pathologic type, staining method, adjuvant therapy, 5-year survival rate and hazard ratio (HR) of OS or RFS were collected. If the HR was not reported in the original article, we would calculate HR from reported data or survival curves according to the methods described by Tierney *et al*.^[@CR27]^. For studies reported 2, 3, or 4-year survival instead of 5-year survival, the 5-year survival rate would be calculated, if possible, according to the survival curves too. Statistical heterogeneity among studies was examined using the Cochrane Q test by calculating the I^2^ value^[@CR28]^. The I^2^ value greater than 50% or p value less than 0.05 were considered to represent significant heterogeneity. The pooled HR and the 95% confidence interval (CI) were calculated using the Z test. The pooled HR and the 95% CI were calculated using the Mantel-Haenszel formula (fixed-effect model) when heterogeneity was not detected (p \> 0.05), or using the DerSimonian-Laird formula (random-effect model) when heterogeneity was significant (p \< 0.05)^[@CR29]^. Subgroup analyses were conducted by confounding factors to detect the source of heterogeneity and assess the effect of those factors on results. Publication bias was evaluated using the funnel plot and the Begg's test^[@CR30]^. Influence analyses were conducted to access how robust the pooled estimators were by removing individual studies. An individual study was suspected of excessive influence if the point estimate of its omitted analysis was outside the 95% CI of the combined analysis. Statistical analyses were performed with Comprehensive Meta Analysis professional version 2.2 (Biostat Inc, Englewood NJ, [www.meta-analysis.com](http://www.meta-analysis.com)).

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

Electronic search identified 731 potentially relevant references. Additional 2 references were further identified by checking the reference list. 576 duplicates or clearly irrelevant references were excluded through reading the abstracts. 157 references were read in full and 97 references were excluded for irrelevance, 41 references were excluded for lack of data on comparisons or outcomes and 3 references were excluded for repeated data. Finally, 16 references fulfilled the inclusion criteria and provided data for the meta-analysis^[@CR11]--[@CR24],\ [@CR31],\ [@CR32]^ (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Flowchart of the identification of relevant studies.

Characteristics of included studies {#Sec9}
-----------------------------------

All 16 included articles were cohort studies published from 2004 to 2015^[@CR11]--[@CR24],\ [@CR31],\ [@CR32]^. This study included 16916 patients, 3667 (21.7%) of them had PL1 and 1512 (8.9%) had PL2. Potential confounders, such as tumor size, age, gender, history of smoking, tumor differentiation, and type of operation were reported and adjusted in most of these studies. The quality score of included studies ranged from 6 to 8 stars. Hazard ratios of overall survival were available in 15 included studies, 5-year survival rates were reported in 14 included studies and hazard ratios of recurrence-free survival were available in three included studies. Characteristics of the included studies are listed in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of included studies.StudyPeriodAreaMedian Age (year)Tumor StageMedian Follow-up (year)Patient NumberVPI Rate (%)Staining MethodPathologic TypeType of ResectionAdjuvant TherapyQuality ScorePL0PL1PL2Osaki T.^[@CR20]^1992--2001Japan66.5I-III2.93451101927.2%H&E and elastic stainingAC, SCC, LCC, ASC and othersPneumonectomy, bilobectomy, lobectomy and segmentectomy/wedgeNA7Shimizu K.^[@CR23]^1979--2001Japan65I-IIINA10552718125.0%H&E and elastic stainingAC, SCC, LCC and ASCPneumonectomy lobectomy and segmentectomyNA7Sakakura N.^[@CR15]^1982--2000Japan62I-IIINA42746219960.8%H&EAC, SCC, LCC and ASCLobectomy pneumonectomy partial resection and segmentectomyNA7Hsu C. P.^[@CR17]^1997--2006Taiwan67I8.6964213464.7%H&EAC, SCC and OthersPneumonectomy bilobectomy and lobectomy segmentectomy wedge resectionNo8Shim H. S.^[@CR22]^1990--2005Korea61I-IIINA6808614125.0%H&E and elastic stainingAC, SCC, LCC and ASCPneumonectomy bilobectomy, lobectomy and segmentectomyNA7Kawase A.^[@CR18]^1979--2006Japan66I-IIINA169341715025.1%H&E and elastic stainingAC, SCC, LCC, ASC and othersPneumonectomy lobectomy segmentectomyNA7Yilmaz A.^[@CR24]^2000--2009TurkeyNAI-IVNA96343742.5%H&E and elastic stainingAC and SCCLobectomy/bilobectomy pneumonectomy lobectomy + chest wall resection and pneumonectomy + chest wall resectionNo7Chang Y. L.^[@CR11]^1990--2008Taiwan64I-IIINANA151170---H&E and elastic stainingAC, SCC and ASCLobectomyYes7Hung J. J.^[@CR12]^1990--2006Taiwan67I-II4.5NA30055---H&E and elastic stainingAC, SCC, LCCs and othersPneumonectomy bilobectomy, lobectomy and sublobar resectionNo7Kudo Y.^[@CR14]^2000--2007Japan66I-III4.66921326221.9%H&E and elastic stainingAC, SCC, LCC and othersPneumonectomy bilobectomy and lobectomyYes7Hung J. J.^[@CR31]^2001--2008Taiwan65.2I4.51151222956.8%H&EACBilobectomy lobectomy and sublobar resectionYes6Kawase A.^[@CR13]^2004Japan67I-II\>5360672721920.8%H&EAC, SCC, LCC, ASC and othersPneumonectomy bilobectomy, lobectomyYes8Nitadori J.^[@CR19]^2000--2008USA68I3.6685811111.8%H&E and elastic stainingACBilobectomy lobectomy, segmentectomy and wedge resectionNo7Oyama M.^[@CR21]^1997--2004Japan65I-III5.510062618625.6%H&E and elastic stainingAC, SCC and othersPneumonectomy and lobectomyNA7Kachala S. S.^[@CR32]^1995--2009USA67.9I-III3.17793367734.6%H&EACNAYes7Adachi H.^[@CR16]^2005--2007Japan67.2I-III5.44621354227.7%H&E and elastic stainingAC, SCC, LCC and othersPneumonectomy bilobectomy, lobectomyYes8\*VPI: visceral pleural invasion; H&E: hematoxylin-eosin staining; AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma; ASC: adenosquamous carcinoma; NA: not available.

Impact of extent of VPI on overall survival {#Sec10}
-------------------------------------------

Fifteen studies contributed data to the analyses of overall survival^[@CR11]--[@CR24],\ [@CR32]^. Thirteen studies compared overall survival between PL1 and PL0 patients^[@CR13]--[@CR24],\ [@CR32]^, thirteen studies compared PL2 with PL0 patients^[@CR11],\ [@CR13]--[@CR24]^ and fourteen studies compared PL2 with PL1 patients^[@CR11]--[@CR24]^. Significant heterogeneity was found among studies in three comparison groups (PL1 vs PL0, I^2^ = 52%, p = 0.012; PL2 vs PL0, I^2^ = 79%, p = 0.000; PL2 vs PL1, I^2^ = 42%, p = 0.042) (Fig. [2](#Fig2){ref-type="fig"}). Random-effect model was used. The pooled HR estimate showed that patients with PL1 or PL2 had poorer overall survival compared with PL0 (PL1 vs PL0, HR = 1.555, 95% CI 1.399, 1.730; PL2 vs PL0, HR = 2.447, 95% CI 1.913, 3.130) (Fig. [2](#Fig2){ref-type="fig"}). And patients with PL2 had even poorer overall survival than patients with PL1 (HR = 1.287, 95% CI 1.114, 1.487) (Fig. [2](#Fig2){ref-type="fig"}).Figure 2Forest plot showing the impact of extent of VPI on overall survival. ^\*^CI: Confidence interval.

Impact of extent of VPI on 5-year survival rate {#Sec11}
-----------------------------------------------

Fourteen studies contributed data to the analyses of 5-year survival rate^[@CR11]--[@CR24],\ [@CR31]^. Twelve studies compared 5-year survival rate between PL1 with PL0 patients^[@CR13]--[@CR24]^, twelve studies compared PL2 with PL0 patients^[@CR13]--[@CR24]^ and fourteen studies compared PL2 with PL1 patients^[@CR11]--[@CR24],\ [@CR31]^. Significant heterogeneity was found among studies in three comparisons (PL1 vs PL0, I^2^ = 78%, p = 0.000; PL2 vs PL0, I^2^ = 73%, p = 0.000; PL2 vs PL1, I^2^ = 66%, p = 0.000) (Fig. [3](#Fig3){ref-type="fig"}). Random-effect model was used. The pooled OR estimate showed that patients with PL1 or PL2 had lower 5-year survival rate than PL0 patients (PL1 vs PL0, OR = 0.515, 95% CI 0.415, 0.640; PL2 vs PL0, OR = 0.441, 95% CI 0.336, 0.579) (Fig. [3](#Fig3){ref-type="fig"}). Moreover, PL2 patients had even lower 5-year survival rate than PL1 patients (OR = 0.706, 95% CI 0.545, 0.915) (Fig. [3](#Fig3){ref-type="fig"}).Figure 3Forest plot showing the impact of extent of VPI on 5-year survival rate. ^\*^CI: confidence interval, PTNB: percutaneous transthoracic needle biopsy.

Impact of extent of VPI on recurrence-free survival {#Sec12}
---------------------------------------------------

Only three studies contributed data to the analyses of recurrence-free survival^[@CR12],\ [@CR19],\ [@CR31]^. Two studies compared recurrence-free survival between PL1 and PL0 patients^[@CR19],\ [@CR31]^, two studies compared PL2 with PL0 patients^[@CR19],\ [@CR31]^ and two studies compared PL2 with PL1 patients^[@CR12],\ [@CR19]^. Significant heterogeneity was found between studies in PL2 versus PL0 comparison group (I^2^ = 90%, p = 0.002), while significant heterogeneity was not found in PL1 versus PL0 and PL2 versus PL1 comparison groups. The pooled HRs estimate showed that patients with PL1 had similar RFS with PL0 patients (HR = 1.271, 95% CI 0.853, 1.893), patients with PL2 had poorer RFS than PL0 patients (HR = 10.592, 95% CI 1.026, 109.335) and patients with PL2 had poorer RFS than patients with PL1 (HR = 1.896, 95% CI 1.163, 3.093) (Fig. [4](#Fig4){ref-type="fig"}).Figure 4Forest plot showing the impact of extent of VPI on recurrence-free survival. ^\*^CI: Confidence interval.

Subgroup analyses {#Sec13}
-----------------

When performing the subgroup analyses of overall survival and 5-year survival rate, studies were stratified by confounding factors including staining method, sample size (VPI), follow-up time, tumor stage, and adjuvant therapy. The observed results showed that the deterioration of overall survival and 5-year survival rate in three comparison groups (PL1 vs PL0, PL2 vs PL0, PL2 vs PL1) were identified in most subgroups (Table [2](#Tab2){ref-type="table"}). Negative results were detected only in only 8 of total 60 subgroups which involved no adjuvant therapy, small sample size (\<300), short follow-up time (\<5 years) or fewer included studies (≤3) (Table [2](#Tab2){ref-type="table"}). For only two included studies of recurrence-free survival the subgroup analyses were not performed on this outcome. All the results of subgroups are shown in Table [2](#Tab2){ref-type="table"}.Table 2Summarized results of subgroup analyses.ComparisonsSubgroupsAnalysis ModelComparisonsHeterogeneityHazard RatioP-valueP-valueI-square %95% Confidence Interval**Overall Survival**PL1 vs PL0OverallRandom140.012521.5561.3991.7300.000Staining methodH&EFixed40.48301.3171.1841.4640.000H&E and elastic stainRandom100.049471.6701.4691.8980.000Sample size (VPI)\<300Fixed90.49701.8111.6112.0360.000\>300Fixed50.59601.3441.2391.4570.000Follow-up time\<5 yearsFixed40.87901.6361.4131.8950.000≥5 yearsFixed40.73301.3321.2061.4710.000Tumor stageEarlyFixed30.312141.3231.1621.5070.000Early and advancedRandom110.022521.6021.4211.8080.000Adjuvant therapyAdjuvant therapyFixed40.176391.3991.2531.5610.000No adjuvant therapyFixed30.61701.6801.2322.2900.001PL2 vs PL0OverallRandom140.000792.4471.9133.1300.000Staining methodH&ERandom30.014771.6711.1282.4760.011H&E and elastic stainRandom110.000802.8442.0823.8860.000Sample size (VPI)\<300Random90.000823.1171.9994.8590.000\>300Fixed50.133431.8081.5862.0610.000Follow-up time\<5 yearsFixed30.97402.6191.7883.8340.000≥5 yearsRandom40.002801.8461.2072.8230.005Tumor stageEarlyFixed30.49101.4611.1681.8290.001Early and advancedRandom110.000802.7752.1043.6590.000Adjuvant therapyAdjuvant therapyRandom40.002802.5821.5014.4410.001No adjuvant therapyFixed30.34271.4440.9142.2820.115PL2 vs PL1OverallRandom150.042421.2871.1141.4870.001Staining methodH&ERandom30.130511.3741.0401.8170.026H&E and elastic stainFixed120.073401.2321.0861.3970.001Sample size (VPI)\<300Fixed90.251221.1260.9501.3340.171\>300Fixed60.079491.4041.2381.5930.000Follow-up time\<5 yearsFixed40.58001.5251.1262.0660.006≥5 yearsFixed40.44001.2191.0221.4540.028Tumor stageEarlyFixed40.312161.3271.0701.6470.010Early and advancedRandom110.023521.2771.0731.5190.006Adjuvant therapyAdjuvant therapyFixed40.245281.4901.2391.7920.000No adjuvant therapyFixed40.061590.9640.6851.3560.834**Five-year survival rate**PL1 vs PL0OverallRandom120.000780.5150.4150.6400.000Staining methodH&EFixed30.71200.7050.6140.8080.000H&E and elastic stainRandom90.020560.4470.3680.5440.000Sample size (VPI)\<300Random80.048510.5140.4030.6560.000\>300Random40.000910.5130.3470.7590.001Follow-up time\<5 yearsFixed30.62900.4830.3700.6300.000≥5 yearsRandom40.005770.5820.4130.8210.000Tumor stageEarlyFixed30.57700.6690.5760.7780.000Early and advancedRandom90.000760.4770.3720.6120.000Adjuvant therapyAdjuvant therapyFixed30.084600.6380.5550.7340.000No adjuvant therapyFixed30.056650.5660.3790.8460.005PL2 vs PL0OverallFixed120.000730.4410.3360.5790.000Staining methodH&ERandom30.001850.5080.2900.8900.018H&E and elastic stainRandom90.001680.4170.3000.5800.000Sample size (VPI)\<300Random80.003670.5830.4140.8220.002\>300Fixed40.88800.2900.2380.3540.000Follow-up time\<5 yearsFixed30.49900.5030.3880.6520.000≥5 yearsRandom40.001830.4470.2350.8540.015Tumor stageEarlyRandom30.001860.5630.1871.6930.306Early and advancedRandom90.002680.4140.3180.5400.000Adjuvant therapyAdjuvant therapyRandom30.047670.4050.2520.6520.000No adjuvant therapyFixed30.87801.0520.6891.6070.816PL2 vs PL1OverallRandom140.000660.7060.5450.9150.009Staining methodH&ERandom30.004820.6590.3781.1470.140H&E and elastic stainRandom110.004610.7320.5351.0000.050Sample size (VPI)\<300Random80.068470.9220.6311.3490.677\>300Random60.002740.5680.4070.7920.001Follow-up time\<5 yearsFixed40.317150.7000.4741.0320.072≥5 yearsFixed40.50800.7860.6250.9880.039Tumor stageEarlyFixed40.279220.7530.5860.9670.026Early and advancedRandom100.000720.6750.4800.9480.023Adjuvant therapyAdjuvant therapyRandom40.017710.5580.3490.8930.015No adjuvant therapyRandom40.013721.4370.5293.9020.477\*H&E: hematoxylin-eosin staining; VPI: Visceral pleural invasion.

Publication bias {#Sec14}
----------------

Visual inspection of the funnel plot for OS and 5-year survival rate outcomes did not show the typically asymmetry associated with publication bias. Evidence of publication bias was also not seen with the Bog's tests of OS and 5-year survival rate (Fig. [5](#Fig5){ref-type="fig"}). We were unable to access publication bias of recurrence-free survival owing to the small number of included studies.Figure 5Funnel plots showing the publication bias of overall survival and 5-year survival rate. (**a**) Overall survival: PL1 vs PL0; (**b**) Overall survival: PL2 vs PL0; (3) Overall survival: PL2 vs PL1; (**d**) 5-year survival rate: PL1 vs PL0; (**e**) 5-year survival rate: PL2 vs PL0; (**f**) 5-year survival rate: PL1 vs PL0.

Sensitivity analyses {#Sec15}
--------------------

The result demonstrated that no individual study had excessive influence on the stability of the pooled effect of each comparison for OS (Fig. [6](#Fig6){ref-type="fig"}) and 5-year survival rate (Fig. [7](#Fig7){ref-type="fig"}). The result of meta-analysis is robust. For the small number of included studies for RFS, the sensitivity analysis could not be performed.Figure 6Forest plot showing the sensitivity analyses of overall survival. ^\*^CI: Confidence interval. Figure 7Forest plot showing the sensitivity analyses of 5-year survival rate. ^\*^CI: Confidence interval.

Discussion {#Sec16}
==========

Visceral pleural invasion, adopted as a T descriptor in the 7th TNM classification of NSCLC, has been reported and constantly studied since 1958^[@CR33]^. The adverse prognostic significance of VPI in resected NSCLC has been generally reported. The prognostic effect of the extent of VPI, especially PL2 versus PL1, has not been well demonstrated. In this study, we investigated the prognostic role of PL0, PL1 and PL2 on resected NSCLC patients respectively and found patients with PL1 and PL2 had worse OS, 5-year survival rate and RFS than those with PL0. Moreover, patients with PL2 have even worse OS, 5-year survival rate and RFS than those with PL0. Our findings demonstrate that VPI adversely impact the prognosis of resected NSCLC patients differently along with the degree of pleura invasion. These findings are important for further design of studies and for choice of aggressive adjuvant therapeutic strategies.

In the present study, we found significant difference of OS and 5-year survival rate between PL1 and PL0, as well as PL2 and PL0. These findings were consistent with those of our previous study and Jiang L. *et al*.^[@CR25],\ [@CR34]^. Our results are also consistent with reported data of the seventh edition and forthcoming eighth edition of the TNM classification of IASLC, published by Rami-Porta *et al*. recently, in which the HR of OS between patients with PL1 and PL0 was 1.44 (95% CI 1.32, 1.58)^[@CR4],\ [@CR35]^. Evidence supports that no matter combined as a single category or divided into two categories (PL1 and PL2), VPI was consistently an adverse prognostic factor in resected NSCLC patients. The result of RFS showed a trend but didn't reach significant survival difference. This reason for this situation may be because only two studies were included. Our results were consistent with the data of forthcoming eighth edition of the TNM classification of IASLC, in which the reported p value of OS for PL2 versus PL1 comparison was 0.012^[@CR35]^. The poorer prognosis of PL2 than PL1 may result from higher risk of pleural dissemination. Kondo *et al*. reported the pleural lavage cytology was positive in 13 of 96 (14%) and 15 of 41 (37%) of patients in the PL1 and PL2 groups, respectively^[@CR36]^. Our results may indicate that tumors with PL2 should be upstaged to higher T stage than those with PL1, for example, from T2a to T2b or T2b to T3. Resected NSCLC patients with PL2 may need more aggressive adjuvant treatment.

Because significant heterogeneity was detected we performed subgroup analyses in order to identify confounding factors and source of heterogeneity. For staining method, not all included studies routinely used the elastic stains when detecting VPI. Part of included studies didn't mention whether elastic stains were used and some of them used elastic stains only when suspicion of VPI. Therefore, there remains some uncertainty regarding the determination of pleura invasion. As noted by Bunker *et al*., the use of an elastic stain is very important for assessing VPI, especially when distinguishing between the PL0 and PL1 status^[@CR37]^. The subgroup analyses according to staining methods still demonstrated that the survival differences among PL2, PL1 and PL0 remained significant no matter the elastic stain was used or not (Table [2](#Tab2){ref-type="table"}). Besides, the patient numbers of some included studies were small, especially in PL1 and PL2 groups, which might be a reason for negative results of some studies. The subgroup analyses also demonstrated that when comparing PL2 with PL1, the survival difference between patients didn't reach statistical significance (Table [2](#Tab2){ref-type="table"}). Additionally, some included studies reported follow-up time shorter than 5 years. We performed the subgroup analyses and found that heterogeneity was not significant within subgroups categorized by 5 years. This means follow-up time was an independent confounding factor of survival outcomes. However, no matter in subgroups with follow-up time less than 5 years or in subgroups with follow-up time at least 5 years, the survival differences among PL2, PL1 and PL0 were significant (Table [2](#Tab2){ref-type="table"}).

There are some other limitations of the present study should be mentioned. First, our results are based on low-level evidence from retrospective studies, in most of which some important confounders were not well adjusted, such as tumor size, adjuvant chemotherapy, smoking status or pathologic types. Second, some studies included the patients received incomplete resection that may impact the survival and recurrence, which is also a potential confounder. Third, another potential source of bias is that some HR estimates were derived from reported data or survival curves which involved extrapolation and assumptions. Fourth, of sixteen included studies, only two were from USA and rest were all from Asian countries. The representativeness is limited. In addition, many studies would not include the PL0, PL1 or PL2 factors when performing the multivariate analysis if the result of univariate analysis is not significant. So, pooling these data might have produced bias. Actually, some significant heterogeneity was detected and most of it was unexplainable.

In conclusion, based on available evidence, extent of VPI impacts the prognosis of resected NSCLC and VPI should be categorized as PL1 and PL2 in the terms of clinical practice and trials. Routine elastic tissue staining should be performed as a standard method for assessing pleural involvement in pleura-based NSCLC. However, worldwide, large-scale and prospective studies, in which elastic staining is used as a standard to diagnose VPI status, are warranted.
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